Compare · ELV vs NVTA
ELV vs NVTA
Side-by-side comparison of Elevance Health Inc. (ELV) and Invitae Corporation (NVTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ELV and NVTA operate in Medical Specialities (Health Care), so they compete in similar markets.
- ELV is the larger of the two at $90.81B, about 39.3x NVTA ($2.31B).
- ELV has hit the wire 3 times in the past 4 weeks while NVTA has been quiet.
- ELV has more recent analyst coverage (23 ratings vs 18 for NVTA).
- Company
- Elevance Health Inc.
- Invitae Corporation
- Price
- $418.31+0.63%
- $0.09-77.21%
- Market cap
- $90.81B
- $2.31B
- 1M return
- +12.19%
- -
- 1Y return
- +7.35%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- 2015
- News (4w)
- 3
- 0
- Recent ratings
- 23
- 18
Elevance Health Inc.
Elevance Health Inc. operates as a health benefits company. It supports consumers, families, and communities across the entire care journey connecting to the care, support, and resources to lead healthier lives. It serves approximately 118 million people through a portfolio of medical, digital, pharmacy, behavioral, clinical, and care solutions. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health Inc. in June 2022. Elevance Health Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Invitae Corporation
Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Latest ELV
- Elevance Health Expands Access to Digital Tools, Helping Bridge the Healthcare Digital Divide
- CAO & Controller Penczek Ronald W exercised 1,531 shares at a strike of $294.30 and sold $617,192 worth of shares (1,531 units at $403.13) (SEC Form 4)
- Elevance Health upgraded by Deutsche Bank with a new price target
- Director Schulman Amy W was granted 563 shares, increasing direct ownership by 258% to 781 units (SEC Form 4)
- Director Schneider Ryan M. was granted 563 shares, increasing direct ownership by 9% to 7,163 units (SEC Form 4)
- Director Peru Ramiro G was granted 563 shares, increasing direct ownership by 6% to 9,908 units (SEC Form 4)
- Director Neri Antonio F was granted 563 shares, increasing direct ownership by 11% to 5,488 units (SEC Form 4)
- Director Jallal Bahija was granted 563 shares, increasing direct ownership by 12% to 5,351 units (SEC Form 4)
- Director Hay Lewis Iii was granted 563 shares, increasing direct ownership by 5% to 12,070 units (SEC Form 4)
- Director Dixon Robert L Jr was granted 563 shares, increasing direct ownership by 5% to 10,885 units (SEC Form 4)
Latest NVTA
- Citizen Health Raises $30 Million to Build AI Advocate for Every Patient, Ushering in a New Era of Patient-Centered Healthcare
- Labcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal
- Reported Earlier, Labcorp Wins Bid For Invitae Assets To Boost Specialty Testing In Oncology And Rare Diseases
- Labcorp Announces Winning Bid for Select Assets of Invitae
- Invitae Enters into Agreement with Labcorp for Sale of Business
- Invitae Publishes its Environmental, Social and Governance (ESG) Report
- Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
- Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification
- Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results
- Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting